Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 24th at 6:00 PM EST.

To Purchase # 8905SC

8905SC 5 µg (With Carrier) $199.00
8905SF 5 µg (Carrier Free) $199.00
8905LC 25 µg (With Carrier) $599.00
8905LF 25 µg (Carrier Free) $599.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Source / Purification

Recombinant human IL-13 (hIL-13) Gly21-Asn132 (Accession #AAK53823) was produced in E. coli at Cell Signaling Technology.

Product Description

Purity:

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIL-13. All lots are greater than 98% pure.


Molecular Formula:

Recombinant hIL-13 does not have a Met on the amino terminus and has a calculated MW of 13,921. DTT-reduced and non-reduced protein migrate as 12 kDa polypeptides with non-reduced protein having slightly greater mobility due to intramolecular cystines. The expected amino-terminal GPVPP of recombinant hIL-13 was verified by amino acid sequencing.


Bioactivity:

The bioactivity of recombinant hIL-13 was determined in a TF-1 cell proliferation assay. The ED50 of each lot is between 0.6-1.2 ng/ml.


Endotoxin:

Less than 0.01 ng endotoxin/1μg hIL-13.


Product Usage Information

Formulation:

With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIL-13. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.


Storage: Stable in lyophilized state at 4°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

IL-13 is produced by T cells and is important in the TH2 response. IL-13 targets include B cells, eosinophils, fibroblasts, mast cells and macrophages (1-3). IL-13 binds specifically to IL-13Rα1 that complexes with IL-4Rα to form the Type II IL-4R. Jak1 and Tyk2 are activated and signal through Stat3 and Stat6 (6). IL-13Rα2 is a different gene product, lacks the intracellular domain, does not complex with IL-4Rα and does not signal (1,6,7). The extracellular domain of IL-13Rα2 is often elevated in diseased states. IL-13 plays key roles in airway hyperresponsiveness (AHR) of allergic asthma (1,4,5) and modulates resistance to parasitic organisms (1).


1.  Wynn, T.A. (2003) Annu Rev Immunol 21, 425-56.

2.  Katz, Y. et al. (1995) Clin Exp Immunol 101, 150-6.

3.  Nakajima, H. and Takatsu, K. (2007) Int Arch Allergy Immunol 142, 265-73.

4.  McKenzie, A.N. et al. (1993) Proc Natl Acad Sci USA 90, 3735-9.

5.  Wills-Karp, M. and Finkelman, F.D. (2008) Sci Signal 1, pe55.

6.  Wills-Karp, M. et al. (1998) Science 282, 2258-61.

7.  Mentink-Kane, M.M. et al. (2004) Proc Natl Acad Sci USA 101, 586-90.


Entrez-Gene Id 3596
Swiss-Prot Acc. P35225


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.